Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis

PURPOSE: Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Tefferi, Ayalew, Verstovsek, Srdan, Barosi, Giovanni, Passamonti, Francesco, Roboz, Gail J., Gisslinger, Heinz, Paquette, Ronald L., Cervantes, Francisco, Rivera, Candido E., Deeg, H. Joachim, Thiele, Juergen, Kvasnicka, Hans M., Vardiman, James W., Zhang, Yanming, Bekele, B. Nebiyou, Mesa, Ruben A., Gale, Robert P., Kantarjian, Hagop M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2009
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979191/
https://ncbi.nlm.nih.gov/pubmed/19652059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.7356
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi